The objectives of this EAG will include:

Development of standardised protocols and reagents for immunogenicity assays for human studies of naturally-occurring immunity and for vaccine trials

Ensure adequate representation of all genotypic/antigenic variants in immunogenicity assays
Generate panels of positive and negative controls and reference sample sets for distribution

In collaboration with the Vaccine Development EAG, standardise protocols for immunogenicity evaluation of candidate vaccines in animal models